Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
出版年份 2015 全文链接
标题
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
作者
关键词
-
出版物
Blood Cancer Journal
Volume 5, Issue 10, Pages e363-e363
出版商
Springer Nature
发表日期
2015-10-23
DOI
10.1038/bcj.2015.91
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
- (2015) A. Palumbo et al. BLOOD
- NCI launches exceptional responders initiative: Researchers will attempt to identify why some patients respond to treatment so much better than others
- (2015) Carrie Printz CANCER
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- In Search of Exceptional Responders
- (2015) Cancer Discovery
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Cancer centers zero in on exceptional responders
- (2014) Cormac Sheridan NATURE BIOTECHNOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
- (2014) M A Dimopoulos et al. Blood Cancer Journal
- Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
- (2013) A J Greenberg et al. LEUKEMIA
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
- (2013) C Bryant et al. Blood Cancer Journal
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- Multiple myeloma and the road to personalised medicine
- (2011) Stephen J Russell et al. LANCET ONCOLOGY
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
- (2010) J.-L. Harousseau et al. BLOOD
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
- (2010) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of complete response in multiple myeloma
- (2009) J.-L. Harousseau et al. BLOOD
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started